BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies

Key Takeaways

• BioMarin has completed its acquisition of Amicus Therapeutics, gaining access to Galafold (migalastat) approved in over 40 countries for Fabry disease treatment
• The deal adds POMBILITI/OPFOLDA combination therapy for late-onset Pompe disease patients weighing ≥40kg who aren’t improving on current treatments
• BioMarin strengthens its position in lysosomal storage disorders with immediate revenue diversification and established global market access

---

BioMarin Strengthens Rare Disease Leadership Through Strategic Acquisition

BioMarin Pharmaceutical Inc. has successfully completed its acquisition of Amicus Therapeutics, significantly expanding its rare disease portfolio with two commercially successful therapies for lysosomal storage disorders. The transaction brings Galafold (migalastat) and the POMBILITI/OPFOLDA combination under BioMarin’s established rare disease commercialization platform.

Global Market Access for Fabry Disease Treatment

Galafold, an oral pharmacological chaperone therapy for Fabry disease, represents a major addition to BioMarin’s portfolio with regulatory approval in more than 40 countries worldwide, including the United States, European Union, United Kingdom, and Japan. This broad international approval provides BioMarin with immediate access to established markets and revenue streams.

Fabry disease, a rare genetic disorder affecting lysosomal enzyme function, has historically been treated primarily with intravenous enzyme replacement therapies. Galafold’s oral administration offers a differentiated treatment approach for patients with amenable genetic mutations.

Pompe Disease Portfolio Enhancement

The acquisition also brings POMBILITI (cipaglucosidase alfa) in combination with OPFOLDA (miglustat) for treating adult patients with late-onset Pompe disease. This combination therapy targets patients weighing ≥40 kg who are not achieving adequate improvement on their current enzyme replacement therapy.

The indication received accelerated approval based on demonstrated reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate levels, highlighting the FDA’s commitment to addressing unmet needs in rare disease populations.

Market Impact and Strategic Rationale

This acquisition positions BioMarin to compete more effectively against established players including Sanofi’s Fabrazyme and Myozyme/Lumizyme franchises, and Takeda’s Replagal. The deal leverages BioMarin’s proven expertise in rare disease development, regulatory navigation, and global commercialization.

Industry analysts view the transaction as strategically sound, providing BioMarin with immediate revenue diversification while maintaining focus on its core competency in ultra-rare genetic disorders. The combined entity benefits from enhanced manufacturing capabilities and expanded distribution networks across key international markets.

Integration and Future Outlook

BioMarin’s integration of Amicus’s commercial operations will focus on maintaining continuity of patient access while realizing operational synergies. The company’s established relationships with rare disease treatment centers and specialized pharmacy networks position it well to optimize market penetration for both therapies.

The acquisition strengthens BioMarin’s pipeline diversity in lysosomal storage disorders, complementing existing programs and providing additional opportunities for combination approaches or next-generation therapies. Success will depend on effective integration execution and continued regulatory support for accelerated approval pathways in rare disease indications.

Regulatory and Reimbursement Considerations

Both acquired therapies operate within the complex rare disease reimbursement landscape, where high treatment costs are balanced against significant unmet medical needs. BioMarin’s experience navigating these challenges across multiple markets provides competitive advantages in optimizing patient access and payer relationships.

The accelerated approval status for the Pompe disease indication requires ongoing confirmatory studies, representing both opportunity and regulatory risk that BioMarin must carefully manage through its development operations.

---

Frequently Asked Questions

What does this acquisition mean for patients currently taking Galafold or POMBILITI/OPFOLDA?

Patients should experience continuity in their treatment access. BioMarin has committed to maintaining existing patient support programs and working with healthcare providers to ensure uninterrupted therapy during the integration process.

How does Galafold compare to existing Fabry disease treatments?

Galafold offers oral administration versus intravenous infusions required for enzyme replacement therapies like Fabrazyme. However, Galafold is only effective for patients with specific genetic mutations amenable to pharmacological chaperone therapy.

Will BioMarin continue developing new treatments for these rare diseases?

Yes, BioMarin plans to leverage its expanded rare disease portfolio to explore next-generation therapies, combination approaches, and pipeline enhancements for lysosomal storage disorders beyond the acquired Amicus programs.